HOOKIPA cuts workforce ~80%, pauses eseba-vec HPV16+ trial, focuses on HB-700

HOOKIPA Pharma Inc.

Workforce reduction of ~80%; implementation begins Q4 2024, substantially complete by H1 2025.
Pauses eseba-vec program; early termination of Phase 1/2 trial for HPV16+ head and neck cancers (not due to safety or efficacy).
Focuses on phase 1-ready HB-700 for KRAS mutated cancers (lung, colorectal, pancreatic); FDA IND clearance received Apr 2024.
Continues HB-500 (HIV) Phase 1b trial and HB-400 (Hepatitis B) program with partner Gilead.
Will seek partnering opportunities for the eseba-vec program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.